FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599269106> ?p ?o ?g. }

• W2599269106 abstract "ABSTRACT Ebola virus (EBOV) and Reston virus (RESTV) are members of the Ebolavirus genus which greatly differ in their pathogenicity. While EBOV causes a severe disease in humans characterized by a dysregulated inflammatory response and elevated cytokine and chemokine production, there are no reported disease-associated human cases of RESTV infection, suggesting that RESTV is nonpathogenic for humans. The underlying mechanisms determining the pathogenicity of different ebolavirus species are not yet known. In this study, we dissected the host response to EBOV and RESTV infection in primary human monocyte-derived macrophages (MDMs). As expected, EBOV infection led to a profound proinflammatory response, including strong induction of type I and type III interferons (IFNs). In contrast, RESTV-infected macrophages remained surprisingly silent. Early activation of IFN regulatory factor 3 (IRF3) and NF-κB was observed in EBOV-infected, but not in RESTV-infected, MDMs. In concordance with previous results, MDMs treated with inactivated EBOV and Ebola virus-like particles (VLPs) induced NF-κB activation mediated by Toll-like receptor 4 (TLR4) in a glycoprotein (GP)-dependent manner. This was not the case in cells exposed to live RESTV, inactivated RESTV, or VLPs containing RESTV GP, indicating that RESTV GP does not trigger TLR4 signaling. Our results suggest that the lack of immune activation in RESTV-infected MDMs contributes to lower pathogenicity by preventing the cytokine storm observed in EBOV infection. We further demonstrate that inhibition of TLR4 signaling abolishes EBOV GP-mediated NF-κB activation. This finding indicates that limiting the excessive TLR4-mediated proinflammatory response in EBOV infection should be considered as a potential supportive treatment option for EBOV disease. IMPORTANCE Emerging infectious diseases are a major public health concern, as exemplified by the recent devastating Ebola virus (EBOV) outbreak. Different ebolavirus species are associated with widely varying pathogenicity in humans, ranging from asymptomatic infections for Reston virus (RESTV) to severe disease with fatal outcomes for EBOV. In this comparative study of EBOV- and RESTV-infected human macrophages, we identified key differences in host cell responses. Consistent with previous data, EBOV infection is associated with a proinflammatory signature triggered by the surface glycoprotein (GP), which can be inhibited by blocking TLR4 signaling. In contrast, infection with RESTV failed to stimulate a strong host response in infected macrophages due to the inability of RESTV GP to stimulate TLR4. We propose that disparate proinflammatory host signatures contribute to the differences in pathogenicity reported for ebolavirus species and suggest that proinflammatory pathways represent an intriguing target for the development of novel therapeutics." @default.
• W2599269106 created "2017-04-07" @default.
• W2599269106 creator A5001588098 @default.
• W2599269106 creator A5018476430 @default.
• W2599269106 creator A5022895534 @default.
• W2599269106 creator A5025196559 @default.
• W2599269106 creator A5030646943 @default.
• W2599269106 creator A5036980616 @default.
• W2599269106 creator A5037576881 @default.
• W2599269106 creator A5046356018 @default.
• W2599269106 creator A5060773615 @default.
• W2599269106 creator A5065429280 @default.
• W2599269106 creator A5091590585 @default.
• W2599269106 date "2017-06-01" @default.
• W2599269106 modified "2023-10-16" @default.
• W2599269106 title "Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages" @default.
• W2599269106 cites W1499978168 @default.
• W2599269106 cites W1542029261 @default.
• W2599269106 cites W1603558825 @default.
• W2599269106 cites W1902776119 @default.
• W2599269106 cites W1903310257 @default.
• W2599269106 cites W1937339698 @default.
• W2599269106 cites W1966742128 @default.
• W2599269106 cites W1971189758 @default.
• W2599269106 cites W1977240303 @default.
• W2599269106 cites W1988126326 @default.
• W2599269106 cites W1989656760 @default.
• W2599269106 cites W1995484660 @default.
• W2599269106 cites W1998424117 @default.
• W2599269106 cites W1999969892 @default.
• W2599269106 cites W2017003212 @default.
• W2599269106 cites W2019168201 @default.
• W2599269106 cites W2019730880 @default.
• W2599269106 cites W2022701206 @default.
• W2599269106 cites W2030622694 @default.
• W2599269106 cites W2032154790 @default.
• W2599269106 cites W2032966566 @default.
• W2599269106 cites W2036436901 @default.
• W2599269106 cites W2038501005 @default.
• W2599269106 cites W2043823247 @default.
• W2599269106 cites W2053240442 @default.
• W2599269106 cites W2059118814 @default.
• W2599269106 cites W2059880041 @default.
• W2599269106 cites W2062835892 @default.
• W2599269106 cites W2068563163 @default.
• W2599269106 cites W2077291760 @default.
• W2599269106 cites W2078645984 @default.
• W2599269106 cites W2079031049 @default.
• W2599269106 cites W2082890018 @default.
• W2599269106 cites W2093551262 @default.
• W2599269106 cites W2096009548 @default.
• W2599269106 cites W2099471944 @default.
• W2599269106 cites W2101345948 @default.
• W2599269106 cites W2105746066 @default.
• W2599269106 cites W2108356414 @default.
• W2599269106 cites W2109686486 @default.
• W2599269106 cites W2111428445 @default.
• W2599269106 cites W2114104545 @default.
• W2599269106 cites W2121706409 @default.
• W2599269106 cites W2121722272 @default.
• W2599269106 cites W2127898507 @default.
• W2599269106 cites W2127934565 @default.
• W2599269106 cites W2129860769 @default.
• W2599269106 cites W2130655121 @default.
• W2599269106 cites W2131583337 @default.
• W2599269106 cites W2131848809 @default.
• W2599269106 cites W2133003848 @default.
• W2599269106 cites W2133600490 @default.
• W2599269106 cites W2134526812 @default.
• W2599269106 cites W2135919238 @default.
• W2599269106 cites W2137627132 @default.
• W2599269106 cites W2142957009 @default.
• W2599269106 cites W2144316492 @default.
• W2599269106 cites W2147414431 @default.
• W2599269106 cites W2148892550 @default.
• W2599269106 cites W2157754339 @default.
• W2599269106 cites W2160999690 @default.
• W2599269106 cites W2163321277 @default.
• W2599269106 cites W2169456326 @default.
• W2599269106 cites W2170551349 @default.
• W2599269106 cites W2171864254 @default.
• W2599269106 cites W2177312905 @default.
• W2599269106 cites W2224576990 @default.
• W2599269106 cites W2238727653 @default.
• W2599269106 cites W2291585600 @default.
• W2599269106 cites W2305571463 @default.
• W2599269106 cites W2320122886 @default.
• W2599269106 cites W2343003620 @default.
• W2599269106 cites W2345513470 @default.
• W2599269106 cites W2346302216 @default.
• W2599269106 cites W2415706930 @default.
• W2599269106 cites W2472571895 @default.
• W2599269106 cites W2560447250 @default.
• W2599269106 cites W2571039582 @default.
• W2599269106 cites W2579523860 @default.
• W2599269106 cites W4320995993 @default.
• W2599269106 doi "https://doi.org/10.1128/jvi.00179-17" @default.
• W2599269106 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5432886" @default.
• W2599269106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28331091" @default.
• W2599269106 hasPublicationYear "2017" @default.

• next